Trastuzumab and pertuzumab were given every 3 weeks throughout chemotherapy.
Primary prophylaxis with filgrastim was not administered during the FEC portion of therapy.
Paclitaxel and carboplatin according to the same schedule for nine cycles.
Trastuzumab and pertuzumab were given every 3 weeks throughout chemotherapy.
The primary end point was pCR (ypT0/is, ypN0).
Secondary end point data on EFS, OS, toxicity, and breast conservation are available.
The following results were observed: There was no statistically significant difference in the proportion of patients with pCR between the anthracycline (67%) and non-anthracycline (68%) arm.